Nicole Tyer, MD
Internal Medicine · Los Angeles, CANPI 1346400785
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (53.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Novo Nordisk accounts for 63.7% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2022 at $3,060 and has fallen 71.7% since, to $865 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $51.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$4K
- AbbVie$545
- Amgen$251
- Lilly USA, LLC$235
- Madrigal Pharmaceuticals$168
- Edwards Lifesciences$106
- plus $788 from 16 others
What the payments were for
- Consulting fees$3,06053%
- Food & beverage$2,34641%
- Education$3556%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 23 | $3,667 |
| AbbVie | 27 | $545 |
| Amgen | 11 | $251 |
| Lilly USA, LLC | 9 | $235 |
| Madrigal Pharmaceuticals | 6 | $168 |
| Edwards Lifesciences | 3 | $106 |
| Almatica Pharma LLC | 4 | $96 |
| Pfizer | 3 | $84 |
| Novartis | 4 | $79 |
| Heartflow, Inc. | 3 | $71 |
| Exact Sciences | 3 | $68 |
| Idorsia Pharmaceuticals US Inc | 3 | $62 |
| Boehringer Ingelheim | 2 | $61 |
| Boston Scientific | 2 | $45 |
| Davol Inc. | 1 | $43 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| GSK | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $30 |
| Bayer | 1 | $22 |
| Shield Therapeutics Inc | 1 | $21 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
How this compares
$5,761 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 16 | $21,513 |
| SynthroidLevothyroxine Sodium | 36 | $2,748 |
| Atorvastatin Calcium | 75 | $1,018 |
| Rosuvastatin Calcium | 66 | $811 |
| Bupropion XlBupropion Hcl | 17 | $749 |
| Telmisartan | 11 | $698 |
| Duloxetine Hcl | 16 | $611 |
| Metoprolol Succinate | 28 | $577 |
| Gabapentin | 24 | $522 |
| Amlodipine Besylate | 62 | $511 |
| Pantoprazole Sodium | 20 | $492 |
| Sertraline Hcl | 21 | $465 |
| Losartan Potassium | 38 | $438 |
| Lorazepam | 33 | $296 |
| Metformin Hcl | 18 | $282 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $3,667 | $21,51316 claims |
| AbbVieSynthroid | $545 | $2,74836 claims |
| Almatica Pharma LLCSertraline Hcl | $96 | $46521 claims |
| PfizerPaxlovid | $84 | $017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.